Navigation Links
Goodwin Biotechnology Announces a Collaboration with Spectros Corporation
Date:10/24/2011

PLANTATION, Fla. and PORTOLA VALLEY, Calif., Oct. 24, 2011 /PRNewswire/ -- Goodwin Biotechnology, Inc. (GBI) and Spectros Corporation jointly announced a collaboration for the process development and cGMP manufacturing of an antibody: dye conjugate that will be used in Phase I and Phase II clinical trials.

"The leading surgical treatment for prostate cancer is prostatectomy, or removal of the prostate," noted David Benaron, CEO at Spectros Corporation. "Unfortunately, residual tumor remains at the edge of surgery about 30% of the time, leading to a significantly higher risk of local recurrence of the cancer and higher rates of death. By collaborating with GBI on the conjugation of a fluorescent dye and a monoclonal antibody that has a high level of affinity with the prostate-specific membrane antigen, we aim to identify and minimize the residual tumor, thereby reducing the number of people who have to receive additional treatment such as high doses of radiation. This type of cancer detection, called Molecular Imaging, may represent an important advance in cancer by improving the diagnosis, individualized treatment selection and monitoring, and even survival. We look forward to clinical trials with this agent, ProstaFluor®, beginning next year."

"We're excited about the opportunity to contribute a decade of bioconjugation experience to this important project," said Muctarr Sesay, PhD, Vice President of Process Development at GBI. "The potential of this innovative approach may represent a new paradigm in the way patients are diagnosed and treated, and contribute significantly to the quality of life of those affected by this insidious disease."

About Goodwin Biotechnology, Inc.Goodwin Biotechnology is a fully integrated cGMP contract manufacturer of monoclonal antibodies, recombinant proteins and vaccines. GBI has the expertise and experience in cell line development, process development and GMP manufacturing of recombinant proteins and antibodies, as well as conjugated therapeutic proteins (e.g., antibodies conjugated to linkers for radioimmune therapy and diagnostics, other antibodies, proteins, chemotoxins, or plant toxins) by leveraging our proprietary conjugation technology. By working with GBI, our clients can enhance the value of their product candidates with clear development and manufacturing strategies and a road map to meet product requirements from the milligram, gram and kilogram range as the product candidates move along the clinical approval pathway. With nearly 20 years of experience as an independent contract manufacturer, GBI has worked with companies of all sizes from small university spin-offs to major research institutes, government agencies and large, established biopharmaceutical companies.

About Spectros CorporationSpectros Corporation makes advanced molecular sensing and imaging devices which shed light on life-threatening diseases, including ischemia and cancer. The company's champion product, the T-Stat® broadband Tissue Oximeter, was the first medical device FDA-approved as sensitive to ischemia, an insufficient supply of oxygen to tissue. Spectros also develops molecular diagnostic tools for breast and prostate cancer, including the ProstaFluor® contrast agent described herein. Spectros is a venture-supported private concern and markets its products in the U.S. and internationally.For more information, please contact:Goodwin Biotechnology:Spectros Corporation:Dave Cunningham

Ms. Elizabeth van Thillo-RohlffDirector of Business Development

Director, Marketing and SalesPhone: (954) 327-9639

Phone: 650-529-2865Email: DCunningham@GoodwinBio.com

Email: info@spectros.com
'/>"/>

SOURCE Goodwin Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Goodwin Biotechnology Announces a Collaboration With Alethia Biotherapeutics
2. Goodwin Biotechnology Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
3. HUYA Bioscience International and Tianjin International Joint Academy of Biotechnology and Medicine Form Alliance
4. The Patent Board, IP Tracking and Analysis Firm, Ranks Heskas Science Strength in Biotechnology Industry Top 50
5. Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger
6. Top 450 Biotechnology (Pharmaceuticals) Report (Global)
7. STELARA® Awarded 2011 Prix Galien USA in Best Biotechnology Product Category
8. 2011 Prix Galien USA Final Candidates Announced: Competing for Best Biotechnology Product and Best Pharmaceutical Agent
9. Lilly Announces New Investment to Further Boost Its Biotechnology Capabilities
10. Generex Biotechnology Corporation CEO Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com
11. Generex Biotechnology Corporation CEO to Present Live, Online at RetailInvestorConferences.com on May 5th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ORLANDO, Fla. , Feb. 20, 2017   ... will migrate its Amadeus precision medicine platform ... Health,s software currently manages over 110 million patient records ... approach to developing cloud-based, big data solutions built on ... Director of Healthcare and Life Sciences. "The AWS Cloud ...
(Date:2/20/2017)... Research and Markets has announced the addition of the ... report to their offering. ... An increasing number of patients suffering ... tension free repair procedures and increasing demand for minimally invasive ... market. However, Inconsistent reimbursement and the high cost of hernia ...
(Date:2/20/2017)... 20, 2017 According to a new market research ... powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), End ... The market is projected to reach USD 52.37 Billion by 2021 from ... forecast period. Continue Reading ... ...
Breaking Medicine Technology:
(Date:2/20/2017)... , ... February 20, 2017 , ... ... check-in, a cloud-based self-service technology that runs on the Posiflex XT-series of touch ... 1076 during HIMSS17 in Orlando, Florida. The terminal provider Posiflex is ...
(Date:2/20/2017)... Sunapee, NH (PRWEB) , ... February 20, 2017 , ... ReportingMD, a Population Health Software ... rapid growth of the company. The new location will triple the size of the ... location for the town of Sunapee, NH. , “We are excited to expand ...
(Date:2/20/2017)... Tampa, FL (PRWEB) , ... February 20, 2017 ... ... $20,000 gift from Constellation Brands to purchase a new ultrasound-enhanced thrombolysis machine, a ... ultrasonic waves. The gift was facilitated by the Pepin Family Foundation. , “We ...
(Date:2/19/2017)... ... 2017 , ... Orbita, Inc., a leading provider ... Healthwise ® at HIMSS 2017 to showcase a breakthrough in remote ... technology and services, will demonstrate a voice-powered knowedge assistant based on Orbita ...
(Date:2/18/2017)... ... , ... Park Cities Pet Sitter President, Joette White, has been featured on ... The episode, which was posted this week, features a 30-minute interview of White ... Cities Pet Sitter’s being awarded the 2017 National Association of Professional Pet Sitter’s Business ...
Breaking Medicine News(10 mins):